98%
921
2 minutes
20
Acquired hemophilia A is an uncommon disease often presented with bleeding episodes causing a significant mortality risk. The main responsible for the threatening hemorrhagic disorder is the Factor VIII autoantibody's development. Acquired inhibitors' presence is frequently idiopathic, but it can be associated with malignancy, pregnancy, drugs and autoimmune diseases. In this report, we present the first case of acquired hemophilia A associated with primary biliary cholangitis. A 48-year-old man, presented with diffuse oral bleeding after a tooth extraction. Hemostasis testing revealed a markedly prolonged activated partial thromboplastin time. The search for an anti-factor VIII inhibitor returned positive. The etiological investigation concluded primary biliary cholangitis, and the patient was treated with bypassing agent, immunosuppressive therapy, and ursodeoxycholic acid.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980470 | PMC |
http://dx.doi.org/10.1080/20565623.2025.2489329 | DOI Listing |
Semin Thromb Hemost
September 2025
Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom.
Ann Med Surg (Lond)
September 2025
Department of Anesthesiology, Tribhuvan University, Institute of Medicine, Kathmandu, Nepal.
Introduction: Juvenile amyotrophic lateral sclerosis (J-ALS) is extremely rare neurodegenerative motor neuron disorder that begins in early childhood or adolescence, before the age of 25 years old. It is characterized by gradual disease progression with comparison to adult-onset ALS and is often linked to genetic mutations.
Case Presentation: A 16-years-old female presented with long history of generalized weakness since age of 10 years, followed by bilateral sensorineural hearing loss, bulbar symptoms, and limb spasticity.
Thromb Res
August 2025
Congenital Coagulopathies Laboratory, Blood and Tissue Bank, 08005 Barcelona, Spain; Transfusional Medicine Group, Vall d'Hebron Research Institute, Autonomous University of Barcelona (VHIR-UAB), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIB
Acquired haemophilia A (AHA) constitutes the most frequent form of autoimmunity againts coagulation factors. The pathogenic basis of anti-FVIII autoantibodies production remains unknown and our narrative review explores the possible causes and provides an overview of evidence data.
View Article and Find Full Text PDFJ Clin Med
August 2025
Division of Internal Medicine 2, Department of Medicine and Medical Specialties, A. Cardarelli Hospital, 80131 Naples, Italy.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are among the most widespread drugs for the prevention of cardiovascular mortality and morbidity. Nevertheless, they are known to cause bradykinin (BK)-mediated angioedema (AE), a paroxysmal, localized, self-limiting, and potentially fatal swelling of the subcutaneous and/or submucosal tissue, due to a temporary increase in vascular permeability. Unlike hereditary angioedema (HAE), which can be mediated similarly by BK, no diagnostic tools, guidelines, or drugs have yet been approved for the diagnosis and treatment of acute non-allergic drug-induced AE.
View Article and Find Full Text PDFCureus
July 2025
Hematology and Medical Oncology, Bronson Methodist Hospital, Kalamazoo, USA.
Hemophilia A (HA) is an X-linked recessive bleeding disorder caused by a deficiency of factor VIII (FVIII), leading to impaired secondary hemostasis. The cornerstone of HA management is replacement therapy; however, this can induce the formation of neutralizing inhibitors, resulting in a refractory FVIII deficiency that is unresponsive to recombinant therapy. This case report describes the postoperative development of FVIII inhibitors in a patient with mild HA and explores two likely etiologies contributing to inhibitor formation.
View Article and Find Full Text PDF